NCT02939014View on ClinicalTrials.gov

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 7, 2016

Primary Completion Date

August 2, 2018

Study Completion Date

February 3, 2020

Conditions
Hodgkin DiseaseLymphoma, Large-Cell, Anaplastic
Interventions
DRUG

Brentuximab Vedotin

Brentuximab vedotin IV infusion

Trial Locations (7)

100142

Beijing Cancer Hospital, Beijing

100191

Peking University Third Hospital, Beijing

200010

Fudan University Shanghai Cancer Center, Shanghai

210009

Jiangsu Cancer Hospital, Nanjing

210029

Jiangsu Province People's Hospital, Nanjing

510060

Sun Yat-san University Cancer Center, Guangzhou

Unknown

The First Hospital of Jilin University, Changchun

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY